Latest:
Dr. Hurvitz on Sequencing Therapeutic Options in HER2+ Breast Cancer
Sara A. Hurvitz, MD, discusses sequencing therapeutic options for patients with HER2-positive breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Stephen A. Strickland, MD, MSCI
Latest:
ASC4FIRST Trial & Asciminib New FDA Approval: Evaluating Asciminib in First-Line CML Treatment
Panelists discuss how a clinician seeks guidance on implementing asciminib in first-line chronic myeloid leukemia treatment following its FDA approval, including understanding its trial data and determining appropriate patient selection compared with existing tyrosine kinase inhibitor options.
Ajay Goel, PhD, AGAF
Latest:
Dr Goel on the Future of an Exosome-Based Liquid Biopsy Plus the Biomarker CA19-9 to Detect Early-Stage Pancreatic Cancer
Ajay Goel, PhD, AGAF, discusses upcoming clinical studies examining the prognostic biomarker CA19-9 plus an investigational exosome-based liquid biopsy for the detection of early-stage pancreatic cancer.
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center
Latest:
Dr Landgren on the Utility of Tocilizumab Prophylaxis in Relapsed/Refractory Multiple Myeloma
C. Ola Landgren, MD, PhD, discusses tocilizumab prophylaxis in relapsed/refractory myeloma treated with teclistamab, elranatamab, or talquetamab.
Quoc-Dien Trinh, MD
Latest:
Dr. Trinh on the Recovery of Cancer Screening Tests Following First COVID-19 Pandemic Peak
Quoc-Dien Trinh, MD, discusses findings from a study examining the temporal changes in cancer tests and diagnoses in a large healthcare system in the United States during the COVID-19 pandemic.
Andrea Casadei Gardini, MD, San Raffaele Research Hospital
Latest:
Patient Profile 3: Advanced HCC Treated With Cabozantinib in Second Line
Centering discussion on the final patient profile, panelists consider how they select optimal therapy in the second-line setting of advanced hepatocellular carcinoma.